Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza
- PMID: 2251874
- DOI: 10.1016/0264-410x(90)90250-p
Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza
Abstract
Intranasal inoculation of haemagglutinin (HA) purified from influenza virus A/PR/8/34 (PR8, H1N1) together with cholera toxin B subunit, into Balb/c mice resulted in complete protection against PR8 infection in parallel with the induction of high levels of HA-specific IgA and IgG antibodies on the respiratory tract. The respiratory tract IgA and IgG were purified from nasal and lung washings of the immunized mice using affinity columns, and their HA-specific activities were measured by enzyme-linked immunosolvent, plaque neutralization and haemagglutination inhibition assays. The purified IgA and IgG had the following properties: (1) They were able to neutralize virus in vitro. (2) The purified IgA included major antibodies directed against PR8 virus and minor antibodies cross-reactive with A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) virus, while the purified IgG included major antibodies to the homotypic virus, minor antibodies to the H1N1 virus and only a trace amount of antibodies to the H3N2 virus. (3) When separated on a Sephacryl column, most of the IgA anti-HA activities occurred in the polymeric fractions of purified IgA, whereas the IgG anti-HA activities occurred in the monomeric fractions. (4) When passively administered to normal mouse respiratory tract before infection, the purified IgA protected against PR8 infection. These results suggest that HA-specific, polymeric IgA antibodies on the respiratory tract by themselves provide not only protection against the homotypic virus but also higher levels of heterotypic immunity than IgG.
Similar articles
-
Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.Eur J Immunol. 1991 Jun;21(6):1337-44. doi: 10.1002/eji.1830210602. Eur J Immunol. 1991. PMID: 1646112
-
Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.J Immunol. 2002 Mar 15;168(6):2930-8. doi: 10.4049/jimmunol.168.6.2930. J Immunol. 2002. PMID: 11884464
-
Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.Vaccine. 1989 Aug;7(4):314-20. doi: 10.1016/0264-410x(89)90192-8. Vaccine. 1989. PMID: 2815967
-
Studies on the usefulness of intranasal inactivated influenza vaccines.Vaccine. 2010 Aug 31;28(38):6393-7. doi: 10.1016/j.vaccine.2010.05.019. Epub 2010 May 20. Vaccine. 2010. PMID: 20493820 Review.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus.PLoS One. 2011 Apr 18;6(4):e18780. doi: 10.1371/journal.pone.0018780. PLoS One. 2011. PMID: 21533151 Free PMC article.
-
Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.Vaccine. 2009 Aug 27;27(39):5344-8. doi: 10.1016/j.vaccine.2009.06.084. Epub 2009 Jul 14. Vaccine. 2009. PMID: 19607949 Free PMC article. Clinical Trial.
-
mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal Transduct Target Ther. 2022 May 21;7(1):166. doi: 10.1038/s41392-022-01007-w. Signal Transduct Target Ther. 2022. PMID: 35597779 Free PMC article. Review.
-
Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.PLoS One. 2013 Aug 8;8(8):e70527. doi: 10.1371/journal.pone.0070527. eCollection 2013. PLoS One. 2013. PMID: 23950951 Free PMC article.
-
Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.J Virol. 2013 Jan;87(1):363-71. doi: 10.1128/JVI.02330-12. Epub 2012 Oct 17. J Virol. 2013. PMID: 23077318 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous